Skip to main content
Peptides/Regenerative

TB-500

Grade B

Widely used in veterinary medicine and reported anecdotally by athletes for muscle, tendon and ligament recovery. Human clinical data is limited to small pilot studies in dermal wound healing.

Category
Regenerative
Evidence grade
B
Route
Subcutaneous or intramuscular injection
Half-life
~2 hours (short systemic), with sustained tissue effects
Typical dose
2–5 mg
Frequency
2× per week loading (4 weeks), then 2–5 mg weekly maintenance
Cycle length
6–8 week loading phase, then maintenance
Best timing
Any time of day; rotate injection sites
Why TB-500 matters

Soft tissue regeneration. Widely used in veterinary medicine and reported anecdotally by athletes for muscle, tendon and ligament recovery. Human clinical data is limited to small pilot studies in dermal wound healing.

  • Accelerated soft-tissue and tendon recovery in preclinical models
  • Improved range of motion after acute injury (case reports)
  • Wound healing and reduced fibrosis
  • Cardiac repair signal in animal MI models
Typical dose
2–5 mg
Frequency
2× per week loading (4 weeks), then 2–5 mg weekly maintenance
Route
Subcutaneous or intramuscular injection
Evidence
Grade B

Mechanism of Action

Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.

Typical Protocol

Dose
2–5 mg
Frequency
2× per week loading (4 weeks), then 2–5 mg weekly maintenance
Duration
6–8 week loading phase, then maintenance
Timing
Any time of day; rotate injection sites
Route
Subcutaneous or intramuscular injection
Half-life
~2 hours (short systemic), with sustained tissue effects

Educational reference only — not medical advice.

Pharmacokinetics & Dosing Rationale

TB-500 is administered subcutaneous or intramuscular injection with an approximate systemic half-life of ~2 hours (short systemic), with sustained tissue effects. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2× per week loading (4 weeks), then 2–5 mg weekly maintenance) is designed to match receptor kinetics rather than plasma exposure. Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.

How to Administer

  1. Route: Subcutaneous or intramuscular injection. Typical starting dose 2–5 mg, 2× per week loading (4 weeks), then 2–5 mg weekly maintenance.
  2. Timing: Any time of day; rotate injection sites — keep it the same each dosing day to make effects legible.
  3. Cycle length: 6–8 week loading phase, then maintenance. Reassess with bloods and symptom logs before repeating.
  4. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Reconstitution & Injection Technique

  1. Reconstitute lyophilised powder with bacteriostatic water (0.9% benzyl alcohol) — sterile water is acceptable but shortens shelf life to ~72 hours.
  2. Typical dilution: add 2 mL of bacteriostatic water to a 5 mg vial → 2.5 mg/mL; a 10-unit insulin syringe mark = 0.25 mg.
  3. Inject the diluent slowly against the vial wall — never onto the powder — and gently swirl. Do not shake; peptides denature under shear.
  4. Once reconstituted, store upright in the refrigerator (2–8 °C) and use within 30 days.
  5. Draw the dose with an insulin syringe (29–31G, 8 mm), swab the site with alcohol, pinch subcutaneous tissue on the abdomen or thigh, inject at 90°.

Sterile technique is not optional. Use a fresh needle for every injection.

Cycling & Stacking Strategy

  • Standard protocol: 2–5 mg, 2× per week loading (4 weeks), then 2–5 mg weekly maintenance, for 6–8 week loading phase, then maintenance.
  • Ramp up: start at the lower end of the dose range for the first 7–10 days to gauge tolerance and side effects before titrating.
  • Break periods let receptor sensitivity and endogenous feedback loops normalise — running back-to-back cycles without a wash-out erodes the effect.
  • Common stack: BPC-157, Collagen peptides, Vitamin C. Introduce one compound at a time so you can attribute effect and side effect.

Who This Is For

Good candidates
  • Adults with a specific, measurable goal aligned to soft tissue regeneration.
  • People who already have baseline bloods, a training routine and a sleep protocol in place.
  • Users who can commit to a full cycle, log the protocol, and re-test biomarkers to evaluate response.
  • Anyone working with a clinician willing to supervise off-label or investigational protocols.
Not appropriate for
  • Anyone with active or recent malignancy, or a strong family cancer history where mechanism is angiogenic or growth-promoting.
  • Pregnant or breastfeeding women — human safety data is absent for almost all research peptides.
  • Adolescents and anyone under 21 whose endocrine axis is still developing.
  • People unwilling to run baseline and post-cycle bloods.
  • Specific contraindications for TB-500: Active malignancy (theoretical angiogenic concern); Pregnancy and lactation.

What to Monitor

Injury / pain score (VAS 0–10)Log weekly at rest and after loading — the primary outcome you care about.
Range of motion / functional testRepeat the same test weekly to see objective recovery.
Skin, mole & lymph checkAngiogenic peptides warrant a baseline dermatology check.
Take it with you

Download a printable version of this checklist to log baseline, weekly and post-cycle results.

Reported Benefits

  • Accelerated soft-tissue and tendon recovery in preclinical models
  • Improved range of motion after acute injury (case reports)
  • Wound healing and reduced fibrosis
  • Cardiac repair signal in animal MI models

Safety Profile

Side effects
  • Injection site reactions
  • Temporary lethargy or head rush after dosing
  • Long-term human safety not characterized
Contraindications
  • Active malignancy (theoretical angiogenic concern)
  • Pregnancy and lactation
AnticoagulantsTheoretical effect on tissue remodeling — caution.
BPC-157Frequently co-stacked; no formal interaction studies.
Storage & handling
  • Unreconstituted vials: store at 2–8 °C long-term; brief room-temperature excursions during shipping are usually acceptable.
  • Reconstituted vials: refrigerate at 2–8 °C, protect from light, use within 30 days.
  • Freezing: acceptable for unreconstituted powder if long-term storage is required; avoid repeated freeze-thaw cycles.
  • Never use a vial that appears cloudy, discoloured or has visible particulates.

Common Mistakes

  • Chasing a bigger dose instead of consistency — TB-500 outcomes track cumulative exposure, not peak concentration.
  • Skipping baseline bloods, so there is no way to know whether the cycle actually moved a biomarker.
  • Stacking three or four novel compounds at once — you lose the ability to attribute any effect or side effect.
  • Ignoring the training, sleep and nutrition fundamentals that are prerequisites for every peptide protocol.
  • Reusing insulin needles or failing to rotate injection sites — a preventable cause of local reactions and lipohypertrophy.

Evidence Grade — B

Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Below are the primary references used to grade TB-500. Follow the links for full-text where available and cross-check against the current literature.

Frequently Asked Questions

What is the typical TB-500 protocol?+

2–5 mg, 2× per week loading (4 weeks), then 2–5 mg weekly maintenance, for 6–8 week loading phase, then maintenance. Route: Subcutaneous or intramuscular injection. Timing: Any time of day; rotate injection sites. Half-life: ~2 hours (short systemic), with sustained tissue effects.

How does TB-500 work?+

Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.

How long before I see results from TB-500?+

Most users track a full 6–8 week loading phase, then maintenance cycle before judging response. Subjective changes can appear within 1–3 weeks, but objective biomarker shifts typically need the full cycle plus repeat labs.

Is TB-500 legal?+

WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use.

What are the main side effects of TB-500?+

Injection site reactions; Temporary lethargy or head rush after dosing; Long-term human safety not characterized.

What should I stack with TB-500?+

Commonly combined with: BPC-157, Collagen peptides, Vitamin C. Introduce one compound at a time to preserve attribution.

What biomarkers should I monitor on TB-500?+

Baseline and post-cycle: full blood count, comprehensive metabolic panel, and category-specific markers for regenerative peptides (see the monitoring section on this page).

Can I run TB-500 back-to-back?+

Off-cycle periods let receptor sensitivity and endogenous feedback normalise. Continuous dosing without a wash-out typically produces diminishing returns and a poorer safety margin.

References

  1. [1]Thymosin β4 and tissue regeneration Annals of the New York Academy of Sciences, 2012

Further reading: Research library → · Protocols →

AttributeTB-500This pageBPC-157Retatrutide
EvidenceGrade BGrade BGrade A
CategoryRegenerativeRegenerativeMetabolic
Best forSoft tissue regenerationTissue repair, gut integrityTriple GIP/GLP-1/glucagon agonist
Typical dose2–5 mg250–500 mcgTitrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency2× per week loading (4 weeks), then 2–5 mg weekly maintenance1–2× dailyOnce weekly
RouteSubcutaneous or intramuscular injectionSubcutaneous or oral (gut-localized)Subcutaneous injection
Legal statusWADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use.Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.Investigational; not yet FDA-approved. Currently available only via clinical trials.
ActionCurrent pageView →View →